Nanologica (Sweden) Performance
| NICA Stock | 1.78 0.01 0.56% |
The company secures a Beta (Market Risk) of 1.04, which conveys a somewhat significant risk relative to the market. Nanologica returns are very sensitive to returns on the market. As the market goes up or down, Nanologica is expected to follow. At this point, Nanologica AB has a negative expected return of -0.41%. Please make sure to verify Nanologica's treynor ratio, value at risk, skewness, as well as the relationship between the maximum drawdown and potential upside , to decide if Nanologica AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nanologica AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 66.4 M | |
| Total Cashflows From Investing Activities | -7.2 M |
Nanologica |
Nanologica Relative Risk vs. Return Landscape
If you would invest 245.00 in Nanologica AB on August 29, 2024 and sell it today you would lose (67.00) from holding Nanologica AB or give up 27.35% of portfolio value over 90 days. Nanologica AB is generating negative expected returns and assumes 4.0218% volatility on return distribution over the 90 days horizon. Simply put, 35% of stocks are less volatile than Nanologica, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Nanologica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nanologica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nanologica AB, and traders can use it to determine the average amount a Nanologica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1029
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NICA |
Estimated Market Risk
| 4.02 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nanologica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nanologica by adding Nanologica to a well-diversified portfolio.
Nanologica Fundamentals Growth
Nanologica Stock prices reflect investors' perceptions of the future prospects and financial health of Nanologica, and Nanologica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nanologica Stock performance.
| Return On Equity | -0.89 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 436.11 M | |||
| Shares Outstanding | 36.15 M | |||
| Price To Book | 44.50 X | |||
| Price To Sales | 87.40 X | |||
| Revenue | 12.91 M | |||
| EBITDA | (31.13 M) | |||
| Total Debt | 1.33 M | |||
| Book Value Per Share | 2.05 X | |||
| Cash Flow From Operations | (46.49 M) | |||
| Earnings Per Share | (1.88) X | |||
| Total Asset | 98.32 M | |||
About Nanologica Performance
Assessing Nanologica's fundamental ratios provides investors with valuable insights into Nanologica's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nanologica is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Nanologica AB performance evaluation
Checking the ongoing alerts about Nanologica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nanologica AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nanologica AB generated a negative expected return over the last 90 days | |
| Nanologica AB may become a speculative penny stock | |
| Nanologica AB has high historical volatility and very poor performance | |
| Nanologica AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.91 M. Net Loss for the year was (44.83 M) with profit before overhead, payroll, taxes, and interest of 3.5 M. | |
| Nanologica generates negative cash flow from operations | |
| About 62.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Nanologica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nanologica's stock is overvalued or undervalued compared to its peers.
- Examining Nanologica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nanologica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nanologica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nanologica's stock. These opinions can provide insight into Nanologica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nanologica Stock Analysis
When running Nanologica's price analysis, check to measure Nanologica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanologica is operating at the current time. Most of Nanologica's value examination focuses on studying past and present price action to predict the probability of Nanologica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanologica's price. Additionally, you may evaluate how the addition of Nanologica to your portfolios can decrease your overall portfolio volatility.